| abstract |
The present invention relates to a compound having a structure represented by formula I, or a pharmaceutically acceptable salt, solvate, active metabolite, polymorph, ester, optical isomer or prodrug thereof, a pharmaceutical composition comprising the compound having the structure represented by formula I, and use thereof as a bruton tyrosine kinase inhibitor having high selectivity for BTK(C481S) mutants and used for preparing a drug for preventing or treating heteroimmune diseases, autoimmune diseases, or cancers. |